Celsius Therapeutics became the latest biopharma spin-out from Third Rock Ventures, which also led the Cambridge, Mass.-based company's $65 million series A financing. GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other undisclosed investors participated in the round for Celsius, which is seeking to develop precision medicines in autoimmune diseases and cancer by drilling genomic insights to the single cell level to understand which cells drive disease and identify the genes that trigger their malfunction.